Synthesis, Computational Analysis and In-vitro anti-inflammatory activities of Naproxen Derivatives by Lipoxygenase and Cyclooxygenase Inhibitory Pathway

Abstract

Enzymes that facilitate the transformation of arachidonic acid into prostaglandins include Lipoxygenase and Cyclooxygenase, which play a crucial role in pro-inflammatory processes. Allopathic medications that inhibit cyclooxygenase are classified as Nonsteroidal anti-inflammatory drugs (NSAIDs), which exhibit significant anti-inflammatory properties, also have several adverse effects, particularly on the gastrointestinal mucosa, attributed to their various functional groups. Hence, present research work is designed to develop new, safer anti-inflammatory derivatives of naproxen that possess dual inhibition capabilities for both Cyclooxygenase and Lipoxygenase pathways, while also enhancing the safety profile.Four derivatives of Naproxen (NS9-NS12) were synthesized through a three-step process and were characterized by 1H NMR, 13CNMR, 19FNMR. Additionally, the safety profile was checked according to OECD guidelines 423 where a single dose of 2000 mg/kg (b.wt) of all derivatives was administered through oral route, while in- vitro anti-inflammatory activity was assessed through the Lipoxygenase and Cyclooxygenase inhibitory pathways. Derivatives were found safe up to dose 2000 mg/kg (b.wt) having no mortality and behavioral changes in any animals treated group. In Cyclooxygenase pathway, NS12 demonstrated high significant inhibitory effect against cyclooxygenase II, with values of 97.33±0.66, 95.78±0.38, 88.65±0.44, 84.67±0.28, 80.55±0.48,77.65±0.53 and 62.65±0.62 achieving an IC50 of <01 μM at concentration 1000-31.25 µg/mL compared with NS9, NS10 and NS11 on the same concentrations. In Lipoxygenase pathway, NS11 exhibited an IC50 of <01 μM, also within the concentration range of 1000-31.25 µg/mL, with percent inhibition values of 91.23± 0.48, 87.44± 0.80, 85.72± 0.61, 81.65± 0.72, 77.86± 0.38, 73.45± 0.77. In comparison with Cyclooxygenase and Lipoxygenase activities, NS12 displayed greater percent inhibition for Cyclooxygenase while for Lipoxygenase NS11. From the docking conformation compound NS11 was found good docking score of -15.9737 formed four polar interactions, one pi-cation and five pi-H linkages with the active residues of the lipoxygenase enzyme.

Keywords

• NS9-NS12
• Synthesis
• Naproxen Derivatives
• Cox1 and Cox2
• Cyclooxygenase and Lipoxygenase

References

1. [1] Tallima H, El Ridi R. Arachidonic acid: Physiological roles and potential health benefits–a review. J Adv Res. 2018; 11: 33-41. https://doi.org/10.1016/j.jare.2017.11.004.
2. [2] Periz GA, Claria J. New approaches to the modulation of the cyclooxygenase-2 and 5-lipoxygenase pathways.Curr Top Med Chem. 2007; 7(3): 297-309. https://doi.org/10.2174/156802607779941378.
3. [3] Smith WL, Urade Y, Jakobsson PJ. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis Chem Rev. 2011; 111(10): 5821-5865. https://doi.org/10.1021/cr2002992.
4. [4] Ferrer MD, Busquets-Cortés C, Capó X, Tejada S, Tur JA, Pons A, Sureda A. Cyclooxygenase-2 inhibitors as a therapeutic target in inflammatory diseases. Curr Med Chem. 2019; 26(18):3225-3241. https://doi.org/10.2174/0929867325666180514112124.
5. [5] Dey R, Dey S, Samadder A, Saxena AK, Nandi S. Natural inhibitors against potential targets of cyclooxygenase, lipoxygenase and leukotrienes. Comb. Chem High Throughput Screen. 2022;25(14):2341-2357. https://doi.org/10.2174/1386207325666210917111847.
6. [6] Rudrapal M, Eltayeb WA, Rakshit G, El-Arabey AA, Khan J, Aldosari SM, Alshehri B, Abdalla M. Dual synergistic inhibition of COX and LOX by potential chemicals from Indian daily spices investigated through detailed computational studies. Sci Rep. 2023;13(1):8656. https://www.nature.com/articles/s41598-023-35161-0.
7. [7] Bjarnason I, Scarpignato C, Holmgren E, Olszewski M, Rainsford KD, Lanas A. Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs. Gastroenterology. 2018;154(3):500-514. https://doi.org/10.1053/j.gastro.2017.10.049.
8. [8] Nedeljković N, Dobričić V, Bošković J, Vesović M, Bradić J, Anđić M, Kočović A, Jeremić N, Novaković J, Jakovljević V, Vujić Z. Synthesis and investigation of anti-inflammatory activity of new thiourea derivatives of naproxen. Pharmaceuticals. 2023;16(5):666. https://doi.org/10.3390/pharmaceutics16010001.

9. [9] Sarigol D, Uzgoren-Baran A, Tel BC, Somuncuoglu EI, Kazkayasi I, Ozadali-Sari K, Unsal-Tan O, Okay G, Ertan M, Tozkoparan B. Novel thiazolo [3, 2-b]-1, 2, 4-triazoles derived from naproxen with analgesic/anti-inflammatory properties: Synthesis, biological evaluation and molecular modeling studies. Bioorg Med Chem. 2015;15;23(10):2518-2528. https://doi.org/10.1039/C5RA02995C.
10. [10] Gatphoh BF, Aggarwal NN, Shankar MK, Revanasiddappa BC. In Silico Studies, Synthesis, and In Vitro Cytotoxicity Studies of 1,3,4-Oxadiazole Derivatives. J Chem Technol Metall. 2022;57(6): 1114-1121. https://journal.uctm.edu/node/j2022-6/5_22-45_JCTM_57_6_pp1114-1121.pdf.
11. [11] Elhenawy AA, Al-Harbi LM, Moustafa GO, El-Gazzar MA, Abdel-Rahman RF, Salim AE. Synthesis, comparative docking, and pharmacological activity of naproxen amino acid derivatives as possible anti-inflammatory and analgesic agents. Drug Des Devel Ther. 2019; 24:1773-1790. https://doi.org/10.2147/DDDT.S196276.
12. [12] Ammar YA, Fayed EA, Bayoumi AH, Saleh MA, El-Araby ME. Design and synthesis of pyridine-amide based compounds appended naproxen moiety as anti-microbial and anti-inflammatory agents. Am J PharmTech Res. 2015;5:245-273. https://www.researchgate.net/publication/312590590.
13. [13] Kappe CO, Dallinger D. The impact of microwave synthesis on drug discovery. Nat Rev Drug Discov 2006;5(1):51-63. https://doi.org/10.1038/nrd1926.,
14. [14] Ha MW, Paek SM. Recent advances in the synthesis of ibuprofen and naproxen. Molecules. 2021; 26(16): 4792. https://doi.org/10.3390/molecules26164792.
15. [15] Han Mİ, Atalay P, Tunç CÜ, Ünal G, Dayan S, Aydın Ö, Küçükgüzel ŞG. Design and synthesis of novel (S)- Naproxen hydrazide-hydrazones as potent VEGFR-2 inhibitors and their evaluation in vitro/in vivo breast cancer models. Bioorg Med Chem. 2021;37:116097.https://doi.org/10.1016/j.tet.2022.132797.
16. [16] Shah NZ, Khan A, Halim SA, Avula SK, Islam NU, Khan I, Karim N, Kifayatullah M, Khalid A, Alhazmi HA, Abdalla AN. Efficient microwave synthesis of flurbiprofen derivatives and their enhancement of efficacy in chronic inflammatory pain models and gastro-protective potential in post-operative model. J Biomol Struct Dyn. 2024;23 1- 6. https://doi.org/10.1080/07391102.2024.2309645.
17. [17] Bsharat II. Tailored Functionalization of Heterocyclic Derivatives of Carboxylic Acids And Imines: Synthesis, Characterization, And Biological Implications. 2023, Faculty of Graduate Studies, An-Najah National University. https://repository.najah.edu/server/api/core/bitstreams/bab1ca9f-c606-4bc2-a186-fde4adeffe30/content.
18. [18] Kifayatullah M, Mustafa MS, Sengupta P, Sarker MM, Das A, Das SK. Evaluation of the acute and sub-acute toxicity of the ethanolic extract of Pericampylus glaucus (Lam.) Merr. in BALB/c mice. J Acute Dis. 2015; 4(4): 309-15. https://doi.org/10.1016/j.joad.2015.06.010.
19. [19] Aziz MA, Salem IM, Al-Awadh MA, Alharbi AS, Abouzed DE, Allam RM, Ahmed OA, Ibrahim TS, Abuo-Rahma GE, Mohamed MF. Exploration of anti-inflammatory activity of pyrazolo [3, 4-d] pyrimidine/1, 2, 4-oxadiazole hybrids as COX-2, 5-LOX and NO release inhibitors: Design, synthesis, in silico and in vivo studies. Bioorg Chem. 2025; 22:108181. https://doi.org/10.1016/j.bioorg.2018.03.030.
20. [20] Abeer Abdulhadi A. Drug design and synthesis of COX-2 selective inhibitors as potential NSAIDs/Abeer Abdulhadi Abdulqader. 2016, University of Malaya. https://www.semanticscholar.org/paper/Drug-design-and- synthesis-of-cox-2-selective-as-Abdulhadi/de248da402d4975b3a3bece0f69f11a8f711b235.
21. [21] Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput-Aided Drug Des. 2011;7(2):146- 157.https://doi.org/1010.2174/157340911795677602.
22. [22] Nawaz MZ, Attique SA, Ain QU, Alghamdi HA, Bilal M, Yan W, Zhu D. Discovery and characterization of dual inhibitors of human Vanin-1 and Vanin-2 enzymes through molecular docking and dynamic simulation-based approach. Int J Biol Macromol. 2022; 31;213:1088-1097. https://doi.org/10.1016/j.ijbiomac.2022.06.014.
23. [23] Das SK, Sengupta P, Mustapha MS, Sarker MM, Kifayatullah M. Toxicological investigation of ethanolic extract of Epipremnum aureum in rodents. J Appl Pharm Sci. 2015; 4;5(2):057-061. https://doi.org/10.10.7324/JAPS.2015.58.S9.
24. [24] Chandrashekar R, Rai M, Kalal BS. Acute and chronic toxicity studies on ethanolic leaf extracts of Clerodendrum viscosum and Leucas indica in Swiss albino mice. Int J Biochem Mol Biol. 2022;13(4):40-48.
25. [25] Rajakariar R, Yaqoob MM, Gilroy DW. COX-2 in inflammation and resolution. Mol Interv.2006;6(4):199-207. https://doi.org/10.10.1124/mi.6.4.6.
26. [26] El Sayed MT, El-Sharief MA, Zarie ES, Morsy NM, Elsheakh AR, Nayel M, Voronkov A, Berishvili V, Sabry NM, Hassan GS, Abdel-Aziz HA. Design, synthesis, anti-inflammatory antitumor activities, molecular modeling and molecular dynamics simulations of potential naprosyn® analogs as COX-1 and/or COX-2 inhibitors. Bioorg Chem. 2018; 76:188-201. https://doi.org/10.10.1016/j.bioorg.2017.11.002.
27. [27] Elhenawy AA, Al-Harbi LM, El-Gazzar MA, Khowdiary MM, Alosaimi AM. Naproxenylamino acid derivatives: Design, synthesis, docking, QSAR and anti-inflammatory and analgesic activity. Biomed Pharmacother. 2019; 116:109024. https://doi.org/10.10.1016/j.biopha.2019.109024.
28. [28] Elewa M, Shehda M, Hanna PA, Said MM, Ramadan S, Barakat A, Aziz YM. Development of a selective COX-2 inhibitor: from synthesis to enhanced efficacy via nano-formulation. RSC Adv. 2024;14(45):32721- 32732.https://doi.org/1010.1039/d4ra06295g.
29. [29] Sardar A, Daud S, Fakhar-e-Alam M, Siddique MH, Ashraf M, Shahid W, Ejaz SA, Atif M, Ahmad S, Shafeeq S, Afzal M. Design, synthesis, in vitro and in silico studies of naproxen derivatives as dual lipoxygenase and α-glucosidase inhibitors. J Saudi Chem Soc. 2022;26(3):101468. https://doi.org/10.1016/j.jscs.2022.101468.
30. [30] Duggan KC, Walters MJ, Musee J, Harp JM, Kiefer JR, Oates JA, Marnett LJ. Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen. J Med Chem. 2010;285(45):34950-34959. https://doi.org/10.10.1074/jbc.M110.162982.
31. [31] Muhammad N, Khan R, Seraj F, Khan A, Ullah U, Wadood A, Ajmal A, Ali B, Khan KM, Nawaz NU, AlMasoud N. In vivo analgesic, anti-inflammatory and molecular docking studies of S-naproxen derivatives. Heliyon. 2024; 30:10(2): e24267.https://doi.org/1010.1016/j.heliyon.2024.e24267.